Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099) ANNOUNCEMENT APPOINTMENT OF CHAIRMAN AND VICE CHAIRMAN OF THE BOARD MEMBERS AND CHAIRMAN OF THE SPECIAL COMMITTEES UNDER THE BOARD AND CHIEF SUPERVISOR OF THE COMPANY

The board of directors (the "Board") of Sinopharm Group Co. Ltd. (the "Company") is pleased to announce that the first meeting of the Fourth Session of the Board resolved on 20 September 2014 to appoint Chairman and Vice Chairman of the Board, members of the special committees under the Board and the Chief Supervisor of the Company as follows:

ELECTION OF CHAIRMAN AND VICE CHAIRMAN OF THE BOARD

The Board resolved to elect Mr. Li Zhiming as the Chairman of the Board and Mr. Chen Qiyu as the Vice Chairman of the Board.

APPOINTMENT OF MEMBERS OF THE SPECIAL COMMITTEES UNDER THE FOURTH SESSION OF THE BOARD

The Board resolved to appoint the chairman and members of each special committee under the Fourth Session of the Board as follows:

Audit Committee

The audit committee consists of five directors, namely Mr. Tan Wee Seng, Mr. Lian Wanyong, Mr. Li Dongjiu, Mr. Liu Zhengdong and Mr. Zhuo Fumin. Mr. Tan Wee Seng serves as the chairman of the audit committee.

Remuneration Committee

The remuneration committee consists of three directors, namely Mr. Liu Zhengdong, Mr. Li Dongjiu and Mr. Yu Tze Shan Hailson. Mr. Liu Zhengdong serves as the chairman of the remuneration committee.

Nomination Committee

The nomination committee consists of seven directors, namely, Mr. Li Zhiming, Mr. She Lulin, Mr. Wang Qunbin, Ms. Li Ling, Mr. Yu Tze Shan Hailson, Mr. Liu Zhengdong and Mr. Zhuo Fumin. Mr. Li Zhiming serves as the chairman of the nomination committee.

Strategy & Investment Committee

The strategy and investment committee consists of nine directors, namely, Mr. Li Zhiming, Mr. Chen Qiyu, Mr. She Lulin, Mr. Wang Qunbin, Mr. Ma Ping, Mr. Li Dongjiu, Mr. Deng Jindong, Ms. Li Ling and Mr. Tan Wee Seng. Mr. Li Zhiming serves as the chairman of the strategy & investment committee.

ELECTION OF CHIEF SUPERVISOR

The Board is also pleased to announce that the first meeting of the Fourth Session of the Supervisory Committee of the Company resolved on 20 September 2017 to elect Mr. Yao Fang as the Chief Supervisor of the Company.

By order of the Board of

Sinopharm Group Co. Ltd. Li Zhiming

Chairman

Shanghai, the PRC 20 September 2017

As at the date of this announcement, the executive director of the Company is Mr. Li Zhiming; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. She Lulin, Mr. Wang Qunbin, Mr. Ma Ping, Mr. Deng Jindong, Mr. Li Dongjiu, Mr. Lian Wanyong, and Mr. Wen Deyong; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong and Mr. Zhuo Fumin.

* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."

Sinopharm Group Co. Ltd. published this content on 20 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 20 September 2017 08:49:02 UTC.

Original documenthttp://sinopharm.todayir.com/attachment/2017092016470200002925335_en.pdf

Public permalinkhttp://www.publicnow.com/view/917912C766E22A1119832D73B6663BD2F72CF7B1